Abstract:Comparative genomic in situ hybridization (CGH) provides a new possibility for searching genomes for imbalanced genetic material. Labeled genomic test DNA, prepared from clinical or tumor specimens, is mixed with differently labeled control DNA prepared from cells with normal chromosome complements. The mixed probe is used for chromosomal in situ suppression (CISS) hybridization to normal metaphase spreads (CGH-metaphase spreads). Hybridized test and control DNA sequences are detected via different fluorochromes, e.g., fluorescein isothiocyanate (FITC) and tetraethylrhodamine isothiocyanate (TRITC). The ratios of FITC/TRITC fluorescence intensities for each chromosome or chromosome segment should then reflect its relative copy number in the test genome compared with the control genome, e.g., 0.5 for monosomies, 1 for disomies, 1.5 for trisomies, etc. Initially, model experiments were designed to test the accuracy of fluorescence ratio measurements on single chromosomes. DNAs from up to five human chromosome-specific plasmid libraries were labeled with biotin and digoxigenin in different hapten proportions. Probe mixtures were used for CISS hybridization to normal human metaphase spreads and detected with FITC and TRITC. An epifluorescence microscope equipped with a cooled charge coupled device (CCD) camera was used for image acquisition. Procedures for fluorescence ratio measurements were developed on the basis of commercial image analysis software. For hapten ratios 4/1, 1/1 and 1/4, fluorescence ratio values measured for individual chromosomes could be used as a single reliable parameter for chromosome identification. Our findings indicate (1) a tight correlation of fluorescence ratio values with hapten ratios, and (2) the potential of fluorescence ratio measurements for multiple color chromosome painting. Subsequently, genomic test DNAs, prepared from a patient with Down syndrome, from blood of a patient with T-cell prolymphocytic leukemia, and from cultured cells of a renal papillary carcinoma cell line, were applied in CGH experiments. As expected, significant differences in the fluorescence ratios could be measured for chromosome types present in different copy numbers in these test genomes, including a trisomy of chromosome 21, the smallest autosome of the human complement. In addition, chromosome material involved in partial gains and losses of the different tumors could be mapped to their normal chromosome counterparts in CGH-metaphase spreads. An alternative and simpler evaluation procedure based on visual inspection of CCD images of CGH-metaphase spreads also yielded consistent results from several independent observers. Pitfalls, methodological improvements, and potential applications of CGH analyses are discussed.

Detection of chromosomal imbalance in oligodendroglial tumors by comparative genomic hybridization

Quantitative Proteomic Analysis of Oligodendrogliomas with and Without 1p/19q Deletion

Detection of Cryptic Balanced Chromosomal Rearrangements Using High-Resolution Optical Genome Mapping

Detection of Chromosomal Imbalance in Ependymoma by Comparative Genomic Hybridization

Chromosome DNA Imbalances in Human Astrocytic Tumors: A Comparative Genomic Hybridization Study of 63 Chinese Patients

Detection of Chromosomal DNA Imbalance in Medulloblastoma by Comparative Genomic Hybridization

Correlation Between Codeletion of Chromosome 1p/19q and MGMT Promoter Methylation in Oligodendrogliomas

Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma

Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.

Comparative Genomic Hybridization Study of Primary Non-Hodgkin's Lymphoma of Head and Neck

Development Of A Focused Oligonucleotide-Array Comparative Genomic Hybridization Chip For Clinical Diagnosis Of Genomic Imbalance

Analytical and clinical validity of whole-genome oligonucleotide array comparative genomic hybridization for pediatric patients with mental retardation and developmental delay.

Itraq-Based Quantitative Proteomic Analysis for Identification of Oligodendroglioma Biomarkers Related with Loss of Heterozygosity on Chromosomal Arm 1P

Determination of genetic aberrations and novel transcripts involved in the pathogenesis of oligodendroglioma using array comparative genomic hybridization and next generation sequencing

Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization

The Molecular Cytogenetic Aberration Analyzed by Comparative Genomic Hybridization and Its Significance in Diffuse Large B-cell Lymphoma

Detection of Loss of Heterozygosity on Chromosome 1p in Oligodendrogliomas by Fluorescence in Situ Hybridization

Biom-30. Novel Histologic And Molecular Biomarkers For Oligodendroglioma

IDH、TERT and 1p/19q predicting clinical outcomes in patients with anaplastic oligodendroglioma

Cytogenetic Study Of Malignant Ovarian Germ Cell Tumors By Chromosome In Situ Hybridization

Identification of a Novel Homozygous Deletion Region at 6q23.1 in Medulloblastomas Using High-Resolution Array Comparative Genomic Hybridization Analysis